Africa should research the long-term sequelae of mpox.
| dc.contributor.author | Allan Komakech | |
| dc.contributor.author | Brian Ngongheh Ajong | |
| dc.contributor.author | ∙ Danny Kalala | |
| dc.contributor.author | Nora Efire | |
| dc.contributor.author | Cris Kacita | |
| dc.contributor.author | Emmanuel Hasivirwe Vakaniaki | |
| dc.contributor.author | Jonathan Izudi | |
| dc.contributor.author | Laurens Liesenborghs | |
| dc.contributor.author | Nicaise Ndembii | |
| dc.date.accessioned | 2025-02-28T09:42:33Z | |
| dc.date.available | 2025-02-28T09:42:33Z | |
| dc.date.issued | 2024-10 | |
| dc.description | Africa Centres for Disease Control and Prevention, Kinshasa, Democratic Republic of the Congo (AK, NE); Clarke International University, Kampala, Uganda (AK); World Health Organization, Kinshasa, Democratic Republic of the Congo (BNA); Democratic Republic of the Congo National Institute of Public Health, Kinshasa, Democratic Republic of the Congo (DK); National Mpox and Viral Hemorrhagic Fevers Control Program, Ministry of Health, Kinshasa, Democratic Republic of Congo (CK); Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo (EHV); Institute of Tropical Medicine, Antwerp, Belgium (LL); Department of Community Health, Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda (JI); Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia (NN | |
| dc.description.abstract | In July, 2022, WHO declared mpox—a viral zoonotic illness—a public health emergency of international concern, due to the rising number of cases and its spread to many countries outside Africa.1 By May, 2023, reported cases of mpox had reduced in regions outside Africa, leading to the lifting of the emergency declaration. In August, 2023, the WHO Director-called upon state parties to develop national mpox plans that incorporated lessons learned, to strengthen laboratory-based surveillance, to enhance community protection through risk communication, and to comprehensively support research for prevention and control.2 However, mpox remains a critical public health problem in Africa, where it was first identified among humans in 1970, in the Democratic Republic of the Congo (DR Congo).3 | |
| dc.identifier.other | 10.1016/S2214-109X(24)00288-2 | |
| dc.identifier.uri | https://dir.ciu.ac.ug/handle/123456789/1517 | |
| dc.language.iso | en | |
| dc.publisher | The Lancent Global Health. | |
| dc.subject | M.pox | |
| dc.subject | Africa | |
| dc.title | Africa should research the long-term sequelae of mpox. | |
| dc.type | Article |